1. Home
  2. GEG vs ACET Comparison

GEG vs ACET Comparison

Compare GEG & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Great Elm Group Inc.

GEG

Great Elm Group Inc.

N/A

Current Price

$2.15

Market Cap

69.0M

Sector

Technology

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.17

Market Cap

79.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEG
ACET
Founded
1994
1947
Country
United States
United States
Employees
50
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.0M
79.9M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
GEG
ACET
Price
$2.15
$8.17
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$48.33
AVG Volume (30 Days)
11.4K
77.4K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.80
$0.46
52 Week High
$3.51
$9.47

Technical Indicators

Market Signals
Indicator
GEG
ACET
Relative Strength Index (RSI) 45.79 46.22
Support Level $2.05 $7.78
Resistance Level $2.19 $8.68
Average True Range (ATR) 0.06 0.51
MACD -0.01 -0.07
Stochastic Oscillator 0.00 15.96

Price Performance

Historical Comparison
GEG
ACET

About GEG Great Elm Group Inc.

Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: